Source comparison
Hexarelin Half-Life: Peptide Comparison
Understanding what's the half-life of hexarelin requires context against other growth hormone secretagogues used in research. Each peptide's clearance kinetics and receptor interaction profile determine optimal dosing intervals. Hexarelin 70–80 minutes 4–6 hou
This comparison does not assign a generated winner or score.
- Understanding what's the half-life of hexarelin requires context against other growth hormone secretagogues used in research. Each peptide's clearance kinetics and receptor interaction profile determine optimal dosing intervals.
- Hexarelin
- 70–80 minutes
- 4–6 hours
- High affinity for GHS-R1a; moderate cortisol/prolactin elevation
- High. Significant tachyphylaxis after 4–8 weeks daily dosing
- Best for short-term GH peak assessment; chronic use limited by receptor desensitisation
- GHRP-2
- 20–30 minutes
- 2–3 hours
- Moderate GHS-R1a affinity; stronger cortisol co-secretion
- Moderate. Some attenuation after 8–12 weeks
- Shorter functional window requires more frequent dosing; cortisol spike complicates metabolic interpretation
- Ipamorelin
- 90–120 minutes
- 3–4 hours
- High GHS-R1a selectivity; minimal cortisol/prolactin effect
- Low. Sustained response over 12+ weeks
- Longer half-life with cleaner GH selectivity; preferred for extended protocols
- CJC-1295 (DAC)
- 6–8 days
- 7–10 days
- Long-acting GHRH analogue; different mechanism (GHRH receptor)
- Very low. Physiological pulsatility maintained
- Not a ghrelin mimetic; creates sustained GH elevation without discrete pulses
- MK-677 (oral)
- 4–6 hours (active metabolite)
- 24 hours
- Non-peptide ghrelin mimetic; continuous receptor activation
- Moderate. Some studies show maintained response at 12 months
- Oral bioavailability advantage; constant GH elevation rather than pulsatile
- Hexarelin's 70-minute plasma clearance sits between GHRP-2 (shorter) and ipamorelin (longer), but its 4–6 hour GH pulse duration exceeds GHRP-2 significantly. The trade-off: hexarelin produces the most robust GH peak of any peptide secretagogue at equivalent molar doses. Often 30–50% higher than ipamorelin. But receptor desensitisation develops faster. Studies document significant attenuation of the GH response after 4–8 weeks of daily hexarelin administration, whereas ipamorelin maintains 70–80% of initial response at 12 weeks.
- For researchers designing studies: hexarelin works best in short-duration protocols (2–4 weeks) where maximum GH stimulation is the primary endpoint. Ipamorelin suits extended metabolic studies where sustained, moderate GH elevation without tachyphylaxis is required. GHRP-2's shorter functional window makes it less practical for twice-daily protocols. The comparison underscores that what's the half-life of hexarelin in plasma (70–80 minutes) matters far less than the 4–6 hour receptor-mediated effect when selecting the right peptide for a research question.